Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular Risk
NCT06008756Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2023
- Primary completion
- Nov 2029
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 29
01
Overview
A Phase 3 trial of enlicitide in hypercholesterolemia, arteriosclerosis, sponsored by Merck & Co.. Started Oct 2023; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiaarteriosclerosis
Beyond the preview
Go deeper on NCT06008756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06008756.